Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2439-2449

  Tsang, Kwong Y ^a   Zhu, MingZhu ^a   Nieroda, Carol A ^a   Correale, Pierpaolo ^a   Zaremba, Sam ^a   Hamilton, J Michael ^a   Cole, David ^b   Lam, Chan ^c   Schlom, Jeffrey ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; VACCINIA VACCINE;

ADOPTIVE TRANSFER; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOLECULAR STABILITY; MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR REJECTION;

ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, CD58; ANTIGENS, CD8; CARCINOEMBRYONIC ANTIGEN; CELL LINE; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTEGRIN ALPHA4; INTERCELLULAR ADHESION MOLECULE-1; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031418054     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Peace, D. J., Chen, W., Nelson, H., and Cheever, M. A. T cell recognition of transforming proteins encoded by mutated ras protooncogenes. J. Immunol., 146: 2059-2065, 1991.
2. Jung, S., and Schluesener, H. J. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras protein. J. Exp. Med., 173: 273-276, 1991.
3. Tsang, K. Y., Nieroda, C. A., De Filippi, R., Chung, Y. K., Yamaue, H., Greiner, J. W., and Schlom, J. Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res., 3: 183-193, 1994.
4. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
5. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 170: 246-252, 1994.
6. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
7. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
8. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
9. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwuck, R., Humblet, Y., Canon, J-L., Laurent, C., Naeyaert, J-M., Plagne, R., Deraemaeker, R., Knuth, A., Jager, E., Brasseur, F., Herman, J., Coulie, P. G., and Boon, T. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63: 883-885, 1995.
10. Morioka, N., Kikumoto, Y., Hoon, D. S., Morton, D. L., and Irie, R. F. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol. Immunol., 32: 573-581, 1995.
11. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F. C., Bast, R. C., and Finn, O. J. Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 51: 2908-2916, 1991.
12. Agrawal, B., Reddish, M. A., and Longenecker, B. M. In vitro induction of muc-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J. Immunol., 157: 2089-2095, 1996.
13. Tilkin, A-F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M-C., Lefrere, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J-G., and Bressec-de Paillerets, B. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol., 25: 1765-1769, 1995.
14. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 17: 432-436, 1995.
15. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. E., Wharton. J. T., and O'Brian, C. A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol., 151: 225-234, 1993.
16. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
17. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst., 89: 293-300, 1997.
18. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., and Riddell, S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333: 1038-1044, 1995.
19. Heslop, H. E., Ng, C. Y. C., Li, C., Smith, C. A., Loftin, S. K., Krance, R. A., Brenner, M. K., and Rooney, C. M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med., 2: 551-555, 1996.
20. Salgaller, M. L., Weber, J. S., Koenig, S., Yannelli, J. R., and Rosenberg, S. A. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother., 39: 105-116, 1994.
21. Chang, A. E., Yoshizawa, H., Sakai, K., Cameron, M. J., Sondak, Y. K., and Shu, S. Clinical observation on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res., 53: 1043-1050, 1993.
22. Leong, S. P. L., Zhou, Y. M., Granberry, M. E., Want, T. F., Grogan, T. M., Spier, C., Shite, R., Mehta, A., and Lin, A. Y. Generation of cytotoxic effector cells against human melanoma. Cancer Immunol. Immunother., 40: 397-409, 1995.
23. Salgaller, M. L., Afshar, A., Marincola, F. M., Rivoltini, L., Kawakami, Y., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995.
24. Lehner, P. J., Wang, E. C. Y., Moss, P. A. H., Williams, S., Platt, K., Freidman, S. M., Bell, J. I., and Borysiewicz, L. K. Human HLA-A-0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cell bearing the Vβ gene segment. J. Exp. Med., 181: 79-91, 1995.
25. Salvi, S., Segalla, F., Rao, S., Arienti, F., Sartori, M., Bratina, G., Caronni, E., Anichini, A., Clemente, C., Parmiani, G., and Sensi, M. Overexpression of the T-cell receptor β-chain variable region TCRBVI4 in HLA-A2-matched primary human melanomas. Cancer Res., 55: 3374-3379, 1995.
26. Puisieux, I., Even, J., Pannetier, C., Jotereau, F., Favrot, M., and Kourilsky, P. Oligoclonality of tumor infiltrating lymphocytes from human melanomas. J. Immunol., 153: 2807-2818, 1994.
27. Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R., and Cresswell, P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol., 138: 1657-1659, 1987.
28. Hogan, K. T., Shimojo, N., Walk, S. F., Engelhard, V. H., Maloy, W. L., Coligan, J. E., and Biddison, W. E. Mutations in the a 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J. Exp. Med., 168: 725-736, 1988.
29. Richardson, G. S., Dickerson, G. R., Atkins, L., MacLaughlin, D. T., Raam, S., Merk, L. P., and Bradley, F. M. KLEB: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol. Oncol., 17: 213-230, 1984.
30. Gritz, L., Destree, A., Cormier, N., Day, E., Stallard, V., Caiazzo, T., Mazzara, G., and Panicali, D. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol., 64: 5948-5957, 1990.
31. Boyüm, A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood: general sedimentation properties of white blood cells in a 1g gravity field. Scand. J. Clin. Lab. Invest., 97 (Suppl.): 51-76, 1968.
32. Coulie, P. G., Somville, M., Lehmann, F., Hainaut, P., Brasseur, F., Devos, R., and Boon, T. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer, 50: 289-297, 1992.
33. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol., 126: 1614-1619, 1981.
34. Guadagni, F., Witt, P. L., Robbins, P. F., Schlom, J., and Greiner, J. W. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-γ. Cancer Res., 50: 6248-6255, 1990.
35. Chomczynski P, and Sacci, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1994.
36. Nishimura, M. I., Kawakami, Y., Charmley, P., O'Neil, B., Shilyansky, J., Yannelli, J. R., Rosenberg, S. A., and Hood, L. T cell receptor repertoire in tumor infiltrating lymphocytes: analysis of melanoma specific long-term lines. J. Immunother., 16: 85-94, 1994.
37. Pannetier, C., Chochet, M., Darche, S., Casrouge, A., Zoller, M., and Kourilsky, P. The sizes of the CDR3 hypervariable regions of the murine T cell receptor β chains vary as a function of the recombined germ line segments. Proc. Natl. Acad. Sci. USA, 90: 4319-4325, 1993.
38. O'Neil, B. H., Kawakami, Y., Restifo, N. P., Bennink, J. R., Yewdell, J. W., and Rosenberg, S. A. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol., 151: 1410-1418, 1993.
39. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine, 16: 759-768, 1997.
40. Bei, R., Kantor, J., Kashmiri, S. V. S., Abrams, S., and Schlom, J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant CEA in mice primed with the recombinant vaccinia CEA. J. Immunother., 16: 275-282, 1994.
41. Foon, K. A., Chakraborty, M., John, W. J., Sherratt, A., Kohler, H., and Bhattacharya-Chatterjee, M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest., 96: 334-342, 1995.
42. Fagerberg, J., Samanci, A., Yi, Q., Strigard, K., Ryden, U., Wahren, B., and Mellstedt, H. Recombinant carcinoembryonic antigen and granulocyte-macrophage-colony-stimulating factor for active immunization of colorectal carcinoma patients. J. Immunother., 19: 461, 1996.
43. Corny, R. M., Saleh, M. N., Schlom, J., and LoBuglio, A. F. Human immune response to carcinoembryonic antigen tumor vaccines. J. Immunother., 18: 137, 1995.
44. Philip, R., Brunette, E., Alters, S., Gadea, J., Zheng, H., Yau, J., Lebkowski, J., and Philip, M. Gene modified and peptide pulsed dendritic cells for the generation of active immunotherapy strategies. J. Immunother., 19: 467, 1996.
45. Alters, S. E., Gadea, J.R., Sorich, M., O'Donoghue, G., Talib, S., and Philip, R. Dendritic cells pulsed with CEA peptide induce CEA specific CTL with restricted TCR repertoire and an activated phenotype in vitro. J. Immunother., in press, 1997.
46. Sensi, M., Traversar, C., Radrizzani, M., Salvi, S., Maccalli, C., Mortarini, R., Rivoltini, L., Farina, C., Nicolini, G., Wolfel, T., Bnichard, V., Boon, T., Bordingnon, C., Anichini, A., and Parmiani, G. Cytotoxic T lymphocyte clones from different patients display limited T cell receptors variable gene usage in HLA-A2 restricted recognition of MelanA/Mart-1 melanoma antigen. Proc. Natl. Acad. Sci. USA, 92: 5674-5678, 1995.
47. Cole, D. J., Weil, D. P., Shamamian, P., Rivoltini, L., Kawakami, Y., Topalian, S., Jennings, C., Eliyahu, S., Rosenberg, S. A., and Nishimura, M. I. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res., 54: 5265-5268, 1994.
48. Mackensen, A., Carcelain, G., Veil, S., Raynal, M. S., Michalaki, H., Triebel, F., Bosq, J., and Hercend, T. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest., 93: 1397-1402, 1994.
49. Mackensen, A., Ferradini, L., Carcelain, G., Triebel, F., Faure, R., Viel, S., and Hercend, T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res., 53: 3569-3574, 1993.
50. Pichler, W. J., and Wyss-Coray, T. T cells as antigen-presenting cells. Immunol. Today, 15: 312-315, 1994.
51. Wyss-Coray, T., Gallati, H., Pracht, I., Limat, A., Mauri, D., Frutig, K., and Pichler, W. J. Antigen presenting human T cells and antigen presenting B cells induce a similar cytokine profile in specific T cell clones. Eur. J. Immunol., 23: 3350-3357, 1993.
52. Mackay, C. R., and Imhof, B. A. Cell adhesion in the immune system. Immunol. Today, 14: 99-102, 1993.
53. Schmits, R., Kundig, T. M., Baker, D. M., Chumaker, G., Simard, J. J. L., Dancan, G., Wakeham, A., Shahinian, A., Van der Heiden, A., and Backmann, M. F. LFA-1 deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J. Exp. Med., 183: 1415-1426, 1996.